Loading...

鉴定晚期肺腺癌EGFR-T790M耐药基因突变候选生物标志物

BACKGROUND AND OBJECTIVE: Osimertinib is approved by Food and Drug Administration for patients with advanced non-small cell lung cancer carrying EGFR-T790M mutations. Osimertinib therapy was missed in many patients who were unable to perform biopsy due to occult lesion progression or weak body. In t...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo Fei Ai Za Zhi
Format: Artigo
Language:Inglês
Published: 中国肺癌杂志编辑部 2020
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7679218/
https://ncbi.nlm.nih.gov/pubmed/33203197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.20
Tags: Add Tag
No Tags, Be the first to tag this record!